DALLAS & AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) today reported the results of new data analysis from multiple Phase 2 clinical studies showing a statistically significant correlation between the abnormal p53 biomarker and tumor response after treatment with ADVEXIN in patients with head and neck, lung, prostate and Li-Fraumeni Syndrome cancers. These data were presented at the Mary Crowley Medical Research Center Conference on Cancer Gene Therapy in Dallas.
